Publicaciones en las que colabora con Vivencio Barrios Alonso (16)

2013

  1. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus

    JAMA Internal Medicine, Vol. 173, Núm. 18, pp. 1682-1692

2008

  1. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

    The Lancet, Vol. 372, Núm. 9644, pp. 1174-1183

  2. Telmisartan, ramipril, or both in patients at high risk for vascular events

    New England Journal of Medicine, Vol. 358, Núm. 15, pp. 1547-1559

2007

  1. Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: The ELECTRA study

    Therapy, Vol. 4, Núm. 4, pp. 433-440

  2. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study

    Journal of Human Hypertension, Vol. 21, Núm. 6, pp. 479-485

  3. Evolution of blood pressure control in Spain [2]

    Journal of Hypertension

2006

  1. Effect of NSAID on blood pressure among hypertensive patients with a high cardiovascular risk

    Anales de Medicina Interna, Vol. 23, Núm. 9

  2. Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: The FATH study

    Journal of the American Society of Nephrology

  3. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study

    British Journal of Cardiology, Vol. 13, Núm. 6, pp. 434-440

2005

  1. Estudio PREVENCAT: Control del riesgo cardiovascular en atención primaria

    Medicina Clinica, Vol. 124, Núm. 11, pp. 406-410

2004

  1. Perfil clínico de una población hipercolesterolémica española y diferencias entre sexos. Estudios LIPYCARE

    Hipertensión y riesgo vascular, Vol. 21, Núm. 8, pp. 395-402

2003

  1. Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabéticos, en pacientes con hipertensión sistólica aislada y en ancianos. Análisis de subgrupos del estudio ELYPSE

    Hipertensión y riesgo vascular, Vol. 20, Núm. 8, pp. 347-353

2002

  1. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study

    Blood Pressure, Vol. 11, Núm. 2, pp. 95-100

  2. N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients

    Blood Pressure, Vol. 11, Núm. 4, pp. 235-239

2000

  1. Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure

    Journal of Hypertension, Vol. 18, Núm. 11, pp. 1545-1551

1999

  1. The kidney in heart failure: Role of angiotensin II

    Current Opinion in Nephrology and Hypertension, Vol. 8, Núm. 2, pp. 153-156